Health Care

The biopharmaceutical business is buying privately-held Pearl Therapeutics for up to $1.15 billion to build its portfolio of respiratory disease drugs.

The company is reportedly working to regroup its products and brands into four sectors, each led by a president reporting to the chief executive.

The global biopharmaceutical business has entered into a definitive agreement to buy Omthera Pharmaceuticals in a deal valued at $323 million.

The global biopharmaceutical business has entered into a definitive agreement to buy Omthera Pharmaceuticals in a deal valued at $323 million.

The drug giant is looking to prop up shareholder value in face of stiff competition from makers of less-costly generics.

John Bond surprised investors by announcing he had been voted out of the top job at the group's first annual shareholders' meeting.

The health-care company reported a a stronger-than-expected increase in profit as membership grew and raised its full-year outlook.

The health-care company reported a a stronger-than-expected increase in profit as membership grew and raised its full-year outlook.

Shares of the drugmaker dropped after it reported lower-than-expected quarterly earnings and revenue and trimmed its full-year profit outlook.

The German company plans to acquire Conceptus for $1.1 billion in cash.

With the start of the health-care overhaul looming, medical companies have been hurt by Americans making even fewer trips to the doctor's office.

Mathew Martoma, a former portfolio manager at hedge fund SAC Capital Management, has hired a new lawyer to defend him in his insider-trading case.

With less than a month left to confront budget cuts and tax increases, the president will speak to to members of the Business Roundtable today after reaffirming his position on higher tax rates for the wealthiest Americans.

GlaxoSmithKline Plc plans to spend more than $1 billion to raise stakes in its Indian and Nigerian consumer healthcare arms, as Britain's biggest drugmaker deepens its emerging markets and non-prescription consumer health footprint.

Aetna has signed a deal to buy rival Coventry Health Care for $5.7 billion.